SCHEMBL30008855

CC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O

nearest known ligand 0.70

Predicted protein targets (top 8)

	gene	UniProt	supporting neighbours	confidence
▸	NR3C1	P04150	6/20	0.70

▸	GHSR	Q92847	4/20	0.70

▸	NPY2R	P49146	3/20	0.70

▸	GLP1R	P43220	5/20	0.67

▸	ECE1	P42892	1/20	0.67

▸	MUS81	Q96NY9	1/20	0.67

▸	IL23R	Q5VWK5	5/20	0.65

▸	CCKBR	P32239	1/20	0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29736869	0.93	NR3C1 (0.72)	NR3C1GHSRNPY2RGLP1RECE1
SCHEMBL29736864	0.92	NR3C1 (0.72)	NR3C1GHSRNPY2RGLP1RECE1
SCHEMBL29491080	0.91	NR3C1 (0.76)	NR3C1GHSRNPY2RGLP1RECE1
SCHEMBL29983249	0.88	NR3C1 (0.69)	NR3C1GLP1RECE1MUS81IL23R
SCHEMBL31140800	0.88	GLP1R (0.70)	NR3C1GLP1RECE1MUS81CCKBR
SCHEMBL29358003	0.87	NR3C1 (0.66)	NR3C1GLP1RECE1MUS81IL23R
SCHEMBL29360422	0.87	GLP1R (0.88)	NR3C1GLP1RECE1MUS81CCKBR
SCHEMBL29540128	0.86	GLP1R (0.79)	NR3C1GHSRNPY2RGLP1RECE1
SCHEMBL29366649	0.86	GLP1R (0.88)	NR3C1GLP1RECE1MUS81CCKBR
SCHEMBL29462206	0.86	GLP1R (0.88)	NR3C1GLP1RECE1MUS81CCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-4633680-A1	THYCLOTIDE PEPTIDE CONJUGATES WITH CELL PERMEABILITY AND INHIBITORY ACTIVITY	The United States of America, as represented by the Secretary, Department of Health and Human Services (US)	2025-10-22	—	—	EP	disclosed
CN-113286820-B	Methods and compounds for targeting sortilin receptors and inhibiting angiogenesis mimicry	特拉斯福特普拉斯公司	2025-04-08	—	—	CN	disclosed
WO-2024129497-A1	THYCLOTIDE PEPTIDE CONJUGATES WITH CELL PERMEABILITY AND INHIBITORY ACTIVITY	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)	2024-06-20	—	—	WO	disclosed
US-11723932-B2	Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells	SYNLOGIC OPERATING COMPANY, INC. (US)	2023-08-15	—	—	US	disclosed
US-20230226122-A1	MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS	SYNLOGIC OPERATING COMPANY, INC.	2023-07-20	—	—	US	disclosed
US-11471494-B2	Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells	SYNLOGIC OPERATING COMPANY, INC. (US)	2022-10-18	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11723932-B2	Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells	PDCD1, CD274, PDCD4	NR3C1 4346/4885GHSR 3744/4885NPY2R 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.